Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Down 28.3% in September

Key Points

• Estrella Immunopharma's short interest decreased by 28.3% in September, totaling 26,300 shares as of September 30th.
• The company's stock has experienced a significant increase of 24.6%, opening at $2.33 on Thursday, with a 12-month high of $2.42.
• Analysts have mixed ratings, with one "buy" rating and one "sell" rating, resulting in an average rating of "hold" and a target price of $16.00.

Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 26,300 shares, a decrease of 28.3% from the September 15th total of 36,700 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 56,900 shares, the short-interest ratio is currently 0.5 days. Based on an average daily trading volume, of 56,900 shares, the short-interest ratio is currently 0.5 days. Currently, 0.3% of the shares of the company are sold short.

Estrella Immunopharma Trading Up 24.6%

Estrella Immunopharma stock opened at $2.33 on Thursday. Estrella Immunopharma has a 12 month low of $0.63 and a 12 month high of $2.42. The stock's 50 day simple moving average is $1.21 and its two-hundred day simple moving average is $1.03. The firm has a market cap of $86.37 million, a PE ratio of -8.96 and a beta of 0.39.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ESLA. Weiss Ratings reiterated a "sell (e+)" rating on shares of Estrella Immunopharma in a research report on Wednesday, October 8th. D. Boral Capital reiterated a "buy" rating and issued a $16.00 target price on shares of Estrella Immunopharma in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $16.00.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.